Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab plus concurrent chemoradiotherapy in elderly inoperable esophageal squamous cell carcinoma
ChiCTR2100043937Phase 2Recruiting
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Affiliated Hospital of Nantong University. Primary endpoint: Median progression-free survival. Started Apr 2021; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100043937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043937.